Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,902,616
  • Shares Outstanding, K 218,845
  • Annual Sales, $ 4,991 M
  • Annual Income, $ 2,404 M
  • 60-Month Beta 1.31
  • Price/Sales 5.40
  • Price/Cash Flow 10.54
  • Price/Book 2.43
Trade ALXN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 2.25
  • Number of Estimates 11
  • High Estimate 2.62
  • Low Estimate 2.05
  • Prior Year 2.51
  • Growth Rate Est. (year over year) -10.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.27 +10.30%
on 11/02/20
128.54 -3.66%
on 11/13/20
+3.83 (+3.19%)
since 10/27/20
3-Month
102.82 +20.43%
on 09/09/20
128.57 -3.69%
on 10/09/20
+17.72 (+16.70%)
since 08/27/20
52-Week
72.67 +70.40%
on 03/16/20
128.57 -3.69%
on 10/09/20
+9.18 (+8.01%)
since 11/27/19

Most Recent Stories

More News
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval

Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.

ALXN : 123.83 (+0.73%)
HALO : 40.23 (-2.21%)
VNDA : 12.41 (+2.48%)
EIDX : 90.00 (+1.45%)
4 Top Growth Stocks with Huge Upside Potential

While growth stocks have dominated in 2021, many have hit extreme valuations. That's why investors should consider growth stocks with high upside potential. Here are four worth a look: Alexion Pharmaceuticals,...

ALXN : 123.83 (+0.73%)
NEM : 58.16 (+0.66%)
SNY : 51.13 (+1.85%)
LKQ : 35.98 (-0.66%)
Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG

RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("" or the ""), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients,...

ALXN : 123.83 (+0.73%)
MRK : 79.96 (-0.12%)
RLFTF : 0.4435 (+4.11%)
Apellis (APLS) Begins Dosing With Pegcetacoplan in ALS Study

Apellis (APLS) and Sobi dose the first patient in the mid-stage MERIDIAN study, which is investigating pegcetacoplan to address adults with sporadic amyotrophic lateral sclerosis.

ALXN : 123.83 (+0.73%)
ABEO : 1.7300 (+22.70%)
CARA : 14.95 (-0.66%)
APLS : 47.22 (-0.51%)
Alexion Pharm Down 37.0% Since SmarTrend Downtrend Call (ALXN)

SmarTrend identified a Downtrend for Alexion Pharm (NASDAQ:ALXN) on August 6th, 2015 at $193.86. In approximately 64 months, Alexion Pharm has returned 36.97% as of today's recent price of $122.20.

ALXN : 123.83 (+0.73%)
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS(R) (ravulizumab) with Significantly Reduced Infusion Time

--- ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) -

ALXN : 123.83 (+0.73%)
Apellis' (APLS) Blood Disorder Drug Gets FDA's Priority Tag

The FDA accepts Apeliis' (APLS) NDA for pegcetacoplanand and grants priority review for the treatment of paroxysmal nocturnal hemoglobinuria.

ALXN : 123.83 (+0.73%)
ALIM : 4.71 (-0.63%)
APLS : 47.22 (-0.51%)
ASLN : 1.8800 (+0.53%)
3 BioTech Stocks to Buy on the Dip 

As the demand for a COVID-19 vaccine or a treatment is on the rise with the number of coronavirus cases increasing each passing day, Alexion Pharmaceuticals (ALXN), BioNTech (BNTX), and Ultragenyx Pharmaceutical...

BNTX : 109.99 (+4.79%)
ALXN : 123.83 (+0.73%)
RARE : 122.42 (+2.16%)
Should Value Investors Consider Alexion (ALXN) Stock Now?

Let's see if Alexion Pharmaceuticals, Inc. (ALXN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

ALXN : 123.83 (+0.73%)
Sanofi (SNY) Blood Disorder Candidate Gets FDA's Rejection

The FDA gives a complete response letter to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease.

BIIB : 243.78 (+0.84%)
ALXN : 123.83 (+0.73%)
SNY : 51.13 (+1.85%)
GBT : 44.90 (+2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

2nd Resistance Point 125.24
1st Resistance Point 124.53
Last Price 123.83
1st Support Level 122.59
2nd Support Level 121.36

See More

52-Week High 128.57
Last Price 123.83
Fibonacci 61.8% 107.22
Fibonacci 50% 100.62
Fibonacci 38.2% 94.02
52-Week Low 72.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar